SCHEMBL6786444

SCHEMBL6786444

C/C(=C/C(=O)Nc1ccc(C)cc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.78
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
F10 P00742 1/20 0.50
GFER P55789 1/20 0.50
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA4 P22748 1/20 0.46
CA7 P43166 1/20 0.46
DHODH Q02127 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LTB4R Q15722 1/20 0.44
METAP2 P50579 1/20 0.43
PLK1 P53350 2/20 0.43
DEGS1 O15121 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785228 0.91 TERT (0.78) TERTF10KDM4ELTB4RPLK1
SCHEMBL4024783 0.89 TERT (0.80) TERTMEN1KMT2AGFERDHODH
SCHEMBL6785154 0.89 TERT (0.84) TERTMEN1KMT2ADHODHKDM4E
SCHEMBL29966843 0.88 TERT (1.00) TERTMEN1KMT2ADHODHKDM4E
SCHEMBL4022937 0.88 TERT (1.00) TERTMEN1KMT2ADHODHKDM4E
SCHEMBL29362821 0.88 TERT (1.00) TERTMEN1KMT2ADHODHKDM4E
SCHEMBL30760782 0.88 TERT (1.00) TERTMEN1KMT2ADHODHKDM4E
SCHEMBL6783614 0.88 TERT (0.81) TERTGFERDHODHKDM4EALDH1A1
SCHEMBL16964998 0.88 TERT (1.00) TERTMEN1KMT2ADHODHKDM4E
SCHEMBL29355750 0.88 TERT (1.00) TERTMEN1KMT2ADHODHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885MEN1 896/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.